在TDI诱导的类固醇不敏感喘中,GLUT1调解支气管上皮层E-cadherin干扰
Yanhua Lv1, Sudan Gan2, Zemin Chen2
1Department of Respiratory and Critical Care Medicine, Zhongshan City People's Hospital, Zhongshan, Guangdong, China.
概括
葡萄糖载体1 (GLUT1) 在严重喘中对E-cadherin干扰起着关键作用. 抑制GLUT1有助于恢复E-cadherin功能,在托洛二酸诱导的类固醇不敏感的喘模型中.
科学领域:
- 肺部医学 肺部医学
- 细胞生物学 细胞生物学
- 免疫学 免疫学 免疫学
背景情况:
- 降低E-cadherin的调节是严重喘的特征,特别是对类固醇不敏感的形式.
- 导致喘中E-cadherin干扰的确切机制尚不清楚.
- 这项研究的重点是葡萄糖载体1 (GLUT1) 在E-cadherin失调中的作用.
研究的目的:
- 研究葡萄糖载体1 (GLUT1) 在E-cadherin失调中的作用.
- 为了检查GLUT1在多二酸 (TDI) 诱导的类固醇不敏感喘中的参与.
主要方法:
- 使用TDI敏感化和吸入,建立了对类固醇不敏感喘的小鼠模型.
- 选择性GLUT1抗剂 (WZB117,BAY876) 给小鼠进行呼吸道挑战后.
- 在体外暴露于TDI的初级人类支气管上皮细胞 (HBECs).
主要成果:
- TDI暴露显著增加了肺部和HBECs中的GLUT1表达.
- 用BAY876抑制GLUT1降低了呼吸道过敏反应,炎症,并恢复了E-cadherin的表达.
- 在体外,GLUT1抑制改善了TDI诱导的HBECs中的E-cadherin干扰.
结论:
- 在TDI诱导的类固醇不敏感喘的背景下,GLUT1调节E-cadherin功能障碍.
- 向GLUT1为严重喘提供了潜在的治疗策略.
更多相关视频
相关概念视频
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
236
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
236
01:20Asthma: Pathogenesis and Management
386
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
386
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:19Antiasthma Drugs: Leukotriene Modifiers
276
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
276
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
271
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
271